8-K: Intelligent Bio Solutions Announces Positive Results from Key Pharmacokinetic Study

Intelligent Bio Solutions reports successful initial results from its Pharmacokinetic study, demonstrating that fingerprint sweat is a reliable sample for drug detection, a key step towards FDA 510(k) submission.

Summary

• Intelligent Bio Solutions Inc. has announced positive initial results from its Pharmacokinetic (PK) study.
• The study demonstrates that fingerprint sweat can reliably be used to detect drugs, specifically codeine, with results closely aligning to blood samples.
• The company is seeking FDA 510(k) clearance, which would allow them to introduce their drug screening technology to the US market in 2025.
• The PK study compared opiate levels in fingerprint sweat with those in blood, oral fluid, and urine after codeine administration.
• The study involved 39 healthy adult subjects and used a validated liquid chromatography/tandem mass spectrometry method for analysis.
• The results indicate that fingerprint sweat is a strong indicator of codeine ingestion, validating the company's rapid and non-invasive drug screening method.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful PK study results and the company's progress towards FDA clearance. The language used is optimistic and forward-looking.

Positives

• The PK study successfully demonstrated a strong correlation between drug levels in fingerprint sweat and blood.
• The company is on track to submit its 510(k) application in the fourth quarter of 2024.
• The technology offers a rapid, non-invasive method for drug screening.
• The company is well-positioned to meet the increasing demand for drug testing in safety-critical industries.
• The study used a gold standard analysis method (LC-MS/MS).

Risks

• The company's ability to successfully develop and commercialize its drug and diagnostic tests is subject to risks and uncertainties.
• Securing regulatory approvals is not guaranteed and may be subject to delays.
• The company's expectations may prove to be materially different from actual results.

Future Outlook

The company anticipates submitting its 510(k) application in the fourth quarter of 2024 and expects to introduce its technology to the US market in 2025, pending FDA clearance.

Management Comments

• Harry Simeonidis, President and CEO of Intelligent Bio Solutions, stated that the clinical study reinforces the findings that fingerprint sweat is a reliable sampling approach.
• The CEO also expressed pleasure with the PK study results, highlighting the potential for widespread adoption of their technology.

Industry Context

This announcement is relevant to the medical technology industry, particularly in the area of drug testing and diagnostics. The company's non-invasive approach could disrupt traditional drug testing methods, especially in safety-critical industries.

Comparison to Industry Standards

• The use of liquid chromatography/tandem mass spectrometry (LC-MS/MS) for analysis aligns with industry gold standards for drug detection studies.
• The study's focus on fingerprint sweat as a sample matrix is innovative compared to traditional methods like blood and urine analysis.
• The company's technology aims to provide faster results than traditional methods, which could be a competitive advantage.

Stakeholder Impact

• Shareholders may react positively to the news of successful PK study results and progress towards FDA clearance.
• Employees may be motivated by the company's progress and potential for growth.
• Customers in safety-critical industries may benefit from the company's rapid and non-invasive drug testing technology.
• Suppliers may see increased demand for their products and services as the company expands.

Next Steps

• The company will submit the PK study results and other clinical data as part of its 510(k) submission.
• The company anticipates introducing its technology to the US market in 2025, pending FDA clearance.

Key Dates

Keywords

Pharmacokinetic Study, FDA 510(k), Drug Screening, Fingerprint Sweat, Codeine Detection, Medical Technology, Non-Invasive Testing, Intelligent Bio Solutions, INBS